Abeona Therapeutics (ABEO) vs ADC Therapeutics SA (ADCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Abeona Therapeutics (ABEO) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 46.0% versus a loss of 68.2%. Over five years, ABEO leads with a -86.7% price change compared with -94.2% for ADCT. ADC Therapeutics SA is the larger company by market cap ($180.0 million vs $165.3 million), about 1.1 times the size.
Abeona Therapeutics converts more of its revenue into profit, with a net margin of 1223.1% versus -175.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABEO | ADCT |
|---|---|---|
| Share price | $2.42 | $1.28 |
| Market cap | $165.31M | $180.05M |
| 1-day change | -1.22% | -1.54% |
| YTD return | -54.08% | -63.74% |
| 1-year return | -45.98% | -68.16% |
| 5-year return | -86.74% | -94.23% |
| EPS (TTM) | $-1.16 | $-0.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.82M | $81.36M |
| Revenue growth (YoY) | — | +14.85% |
| Net income (latest FY) | $71.18M | $-142.62M |
| Gross margin | 73.68% | 92.87% |
| Operating margin | -1536.91% | -149.34% |
| Net margin | 1223.08% | -175.31% |
| 52-week high | $7.65 | $4.98 |
| 52-week low | $2.09 | $0.78 |
| Distance from 52-week high | -68.37% | -74.30% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +542.98% | +160.16% |
| Average volume | 1.66M | 1.55M |
| Shares outstanding | 68.31M | 140.66M |
| Employees | 226 | 188 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ABEO has outperformed ADCT by 22.2 percentage points over the past year.
- Abeona Therapeutics is more profitable, keeping 1223.1 cents of every revenue dollar as net income versus -175.3 cents for ADC Therapeutics SA.
About Abeona Therapeutics
ABEO stock →Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Health Care · Biotechnology: Pharmaceutical Preparations · 226 employees
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
ABEO vs ADCT FAQ
Which is bigger, Abeona Therapeutics or ADC Therapeutics SA?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $180.05M compared with $165.31M for Abeona Therapeutics (ABEO).
Which stock has performed better over the past year, ABEO or ADCT?
ABEO returned -45.98% over the past 12 months, compared with -68.16% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are Abeona Therapeutics and ADC Therapeutics SA in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.